Open Access<p>LncRNA LINC01116 Contributes to Cisplatin Resistance in Lung Adenocarcinoma</p>
Author(s) -
Junbin Wang,
Jin Gao,
Qinnan Chen,
Weiyan Zou,
Fen Yang,
Chenchen Wei,
Zhaoxia Wang
Publication year - 2020
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s244879
Subject(s) - cisplatin , a549 cell , viability assay , mtt assay , gene knockdown , apoptosis , vimentin , cell growth , flow cytometry , cancer research , chemistry , cell , microbiology and biotechnology , cell cycle , adenocarcinoma , biology , medicine , cancer , immunology , chemotherapy , biochemistry , immunohistochemistry
Long non-coding RNAs (lncRNAs) have been found to contribute to cisplatin resistance in several cancers; however, the role of lncRNA LINC01116 in cisplatin resistance remains unknown in non-small-cell lung cancer. This study aimed to examine the contribution of LINC01116 to cisplatin resistance in lung adenocarcinoma (LAD).